Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. SPRC
SPRC logo

SPRC Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
10.110
Open
10.000
VWAP
9.39
Vol
832.03K
Mkt Cap
5.62M
Low
8.240
Amount
7.81M
EV/EBITDA(TTM)
--
Total Shares
573.24K
EV
2.72M
EV/OCF(TTM)
--
P/S(TTM)
--
Scisparc Ltd, former Therapix Biosciences Ltd is a Israel-based pharmaceutical company commited into creating and enhancing technologies and assets based on cannabinoid pharmaceuticals. The company is engaged in drug development programs based on repurposing a cannabinoid (Dronabinol): THX-110 for the treatment of Tourette syndrome (TS), for the treatment of Obstructive Sleep Apnea (OSA), and the treatment of Pain; THX-130 for the treatment of Mild Cognitive Impairment (MCI) and Traumatic Brain Injury (TBI); THX-150 for the treatment of infectious diseases; and THX-160 for the treatment of pain.
Show More

Events Timeline

(ET)
2026-03-16
08:30:00
SciSparc Collaborates with Clearmind to File Patent for Depression Treatment
select
2026-03-12 (ET)
2026-03-12
08:00:00
SciSparc's NeuroThera Labs Advances Collaboration with Clearmind on Patent Publication
select
2026-03-10 (ET)
2026-03-10
09:30:00
SciSparc's NeuroThera Acquires 54.01% Stake in CliniQ
select
2026-03-03 (ET)
2026-03-03
20:00:00
Scisparc Ltd Trading Halted, News Pending
select
2026-02-17 (ET)
2026-02-17
17:30:00
SciSparc Files to Sell 23.04M Ordinary Shares
select
2026-02-03 (ET)
2026-02-03
16:40:00
SciSparc Files $50M Mixed Securities Shelf
select

News

seekingalpha
8.5
05-28seekingalpha
PinnedSciSparc Subsidiary Receives Approval for CliniQuantum Acquisition
  • Stock Surge: SciSparc Ltd. (SPRC) saw a 155% increase in stock price on Thursday, primarily driven by its subsidiary NeuroThera Labs receiving conditional approval from the TSX Venture Exchange for its acquisition, reflecting strong market optimism about the deal.
  • Acquisition Details: NeuroThera plans to acquire approximately 54% of CliniQuantum in exchange for 56.6 million common shares, valued at about $9.46 million based on NeuroThera's 20-day volume-weighted average share price, indicating market recognition of its growth potential.
  • Technological Innovation: CliniQuantum focuses on developing quantum simulation and Monte Carlo-based tools aimed at enhancing clinical trial precision by identifying patient subgroups most likely to respond to therapies, showcasing its cutting-edge position in clinical research.
  • Exclusive Licensing Agreement: CliniQuantum's main asset is an exclusive worldwide license agreement with Quantum X Labs related to quantum simulation technologies for clinical trials, which will further strengthen its market competitiveness and drive future technological advancements.
NASDAQ.COM
8.5
05-29NASDAQ.COM
SciSparc Receives Approval to Acquire Stake in Israeli Tech Firm
  • Acquisition Approval: SciSparc Ltd. (SPRC) received regulatory approval from the TSX Venture Exchange for its subsidiary NeuroThera Labs to acquire approximately 54% of CliniQuantum, valued at about $9.46 million, which is expected to enhance its competitive edge in clinical trial data analysis.
  • Stock Surge: SPRC's shares soared nearly 140% to close at $10.55 on Thursday, reflecting strong market enthusiasm for its acquisition plans, which may attract further investor interest in its future growth prospects.
  • Ebola Testing Progress: Co-Diagnostics Inc. (CODX) saw its stock rally over 50% for the third consecutive day amid the Ebola outbreak, indicating the effectiveness of its PCR assay strategy, which is likely to bolster the company's influence in public health.
  • Clinical Trial Initiation: MiNK Therapeutics (INKT) dosed its first patient in a randomized phase 2 trial for acute lung injury, leading to an 18% stock increase, and this advancement could provide crucial data support for its future treatment options, strengthening its market position.
Newsfilter
8.5
03-10Newsfilter
SciSparc Acquires Controlling Interest in CliniQuantum
  • Transaction Overview: SciSparc's majority-owned NeuroThera Labs has signed a share purchase agreement to acquire approximately 54.01% of CliniQuantum's shares for about $9.45 million, with the transaction expected to close within 30 days, marking a strategic expansion into quantum technology.
  • Share Payment Structure: NeuroThera will issue 56,600,000 common shares to the Selling Shareholders, who may also receive up to $2.5 million in earn-out payments based on CliniQuantum's patent applications and fundraising achievements, further incentivizing innovation.
  • Technological Innovation Potential: CliniQuantum focuses on leveraging quantum computing to enhance clinical trials, aiming to accelerate research by processing complex datasets, and this acquisition will strengthen SciSparc's competitive edge in the pharmaceutical industry and drive cutting-edge product development.
  • Future Outlook: The transaction is anticipated to close by March 31, 2026, providing SciSparc an opportunity to enhance its market position in treating central nervous system disorders and achieve long-term growth through technological integration.
Yahoo Finance
8.5
03-10Yahoo Finance
Clearmind Unveils Patent for Innovative Weight Loss Therapy
  • Patent for Innovative Therapy: Clearmind Medicine Inc. has announced an international patent application for a novel therapy combining MEAI and Palmitoylethanolamide, aimed at treating obesity and metabolic dysfunction-associated steatotic liver disease, potentially benefiting over 890 million obese adults worldwide.
  • Significant Market Potential: The global weight loss drugs market was valued at approximately $37 billion in 2025 and is projected to reach $226 billion by 2035, indicating a strong demand for innovative alternatives, positioning Clearmind's new therapy to capture a share of this rapidly growing market.
  • Strengthened Partnerships: The development of this therapy is bolstered by collaboration with NeuroThera Labs Inc., integrating Clearmind's MEAI platform with PEA to offer a safer and more cost-effective treatment option compared to GLP-1 agonists, enhancing the company's competitive edge in the biotech sector.
  • Strategic Development Focus: CEO Dr. Adi Zuloff-Shani emphasized the company's commitment to developing innovative therapies to address underserved metabolic and neurological health issues, further solidifying its leadership position in the biotechnology industry.
NASDAQ.COM
8.5
01-16NASDAQ.COM
Sanofi Secures EU Approval for Teizeild, Demonstrating Significant Efficacy in Type 1 Diabetes
  • New Drug Approval: Sanofi's Teizeild receives EU approval as the first disease-modifying therapy for Stage 2 Type 1 Diabetes, demonstrating a median delay of 48.4 months to Stage 3 T1D, significantly enhancing patient quality of life and strengthening the company's competitive position in diabetes treatment.
  • FDA Approval: Fortress Biotech's ZYCUBO gains FDA approval as the first treatment for Menkes Disease, showing nearly an 80% reduction in mortality risk when used early, laying a solid foundation for future market expansion and revenue growth.
  • Acquisition Deal: Boston Scientific's $14.5 billion acquisition of Penumbra reflects its strategic expansion in interventional therapies, expected to enhance its leadership in vascular treatments and drive future revenue growth.
  • Clinical Trial Progress: Creative Medical's CELZ-201 shows significant improvement in 79% of patients in the ADAPT trial for chronic lower back pain, indicating the therapy's clinical potential and likely attracting further investment and partnership opportunities.
Benzinga
8.5
01-13Benzinga
SciSparc Ltd. Acquires Endoscopy Patents, Shares Drop 12.07%
  • Patent Acquisition: SciSparc announced its definitive agreement to acquire a portfolio of patents and trademarks related to endoscopic systems and medical cameras, which is expected to enhance its presence in the medical device sector and facilitate expansion into new markets.
  • Commercialization Strategy: The company plans to begin commercializing the acquired technologies immediately upon closing the deal, aiming to accelerate market penetration by replicating existing successful distribution models, particularly in North America, Europe, and Latin America.
  • Equity Issuance Terms: Under the agreement, SciSparc will issue ordinary shares representing approximately 19.99% of its outstanding stock to the seller at closing, with the potential to issue pre-funded warrants to optimize its capital structure as needed.
  • Expected Closing Timeline: SciSparc anticipates closing the acquisition by March 8, 2026, contingent upon satisfying customary conditions, including regulatory approvals, which will provide a significant opportunity for the company to enter new medical segments.

Valuation Metrics

The current forward P/E ratio for Scisparc Ltd (SPRC.O) is 0.00, compared to its 5-year average forward P/E of -11.37. For a more detailed relative valuation and DCF analysis to assess Scisparc Ltd's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-11.37
Current PE
0.00
Overvalued PE
26.07
Undervalued PE
-48.81

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
1.42
Current PS
0.00
Overvalued PS
4.48
Undervalued PS
-1.63

Financials

AI Analysis
Annual
Quarterly

Related Community Screener

Momentum stocks
Intellectia · 1440 candidates
Relative Vol: >= 1.50Moving Average Relationship: PriceAboveMA20, PriceAboveMA200Week Price Change Pct: >= $0.00Month Price Change Pct: >= $0.00Macd: bullish
Ticker
Name
Market Cap$
top bottom
AKAN logo
AKAN
Akanda Corp
13.89M
BBGI logo
BBGI
Beasley Broadcast Group Inc
34.79M
ONEG logo
ONEG
OneConstruction Group Ltd
136.96M
MXL logo
MXL
Maxlinear Inc
6.05B
RPGL logo
RPGL
Republic Power Group Ltd
4.44M
CREG logo
CREG
Smart Powerr Corp
23.42M
best swing trades for nest week under $25
Intellectia · 287 candidates
Price: <= $25.00Rsi Category: moderateRelative Vol: >= 1.50List Exchange: XNYS, XNAS, XASEMoving Average Relationship: PriceAboveMA20Week Price Change Pct: $3.00 - $25.00Macd: bullish, positive
Ticker
Name
Market Cap$
top bottom
ALLR logo
ALLR
Allarity Therapeutics Inc
19.94M
SEAT logo
SEAT
Vivid Seats Inc
77.12M
PCSA logo
PCSA
Processa Pharmaceuticals Inc
6.46M
SMSI logo
SMSI
Smith Micro Software Inc
17.54M
SPRC logo
SPRC
Scisparc Ltd
3.14M
BTBD logo
BTBD
Bt Brands Inc
9.48M
Find stocks with low float
Intellectia · 2888 candidates
Region: USShares Outstanding: <= 150,000,000
Ticker
Name
Market Cap$
top bottom
ADTX logo
ADTX
Aditxt Inc
2.59M
GWAV logo
GWAV
Greenwave Technology Solutions Inc
4.33M
GDHG logo
GDHG
Golden Heaven Group Holdings Ltd
5.19M
AREB logo
AREB
American Rebel Holdings Inc
3.47M
IPW logo
IPW
iPower Inc
5.62M
WTO logo
WTO
UTime Ltd
1.44M
3 stocks with RSI below 25
Intellectia · 221 candidates
Rsi Category: oversold
Ticker
Name
Market Cap$
top bottom
WIX logo
WIX
Wix.Com Ltd
4.37B
SOAR logo
SOAR
Volato Group Inc
3.65M
OTLK logo
OTLK
Outlook Therapeutics Inc
32.44M
JTAI logo
JTAI
Jet.AI Inc
5.42M
SPRC logo
SPRC
Scisparc Ltd
4.57M
IPW logo
IPW
iPower Inc
5.62M

Whales Holding SPRC

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is Scisparc Ltd (SPRC) stock price today?

The current price of SPRC is 9.81 USD — it has decreased -7.01

What is Scisparc Ltd (SPRC)'s business?

Scisparc Ltd, former Therapix Biosciences Ltd is a Israel-based pharmaceutical company commited into creating and enhancing technologies and assets based on cannabinoid pharmaceuticals. The company is engaged in drug development programs based on repurposing a cannabinoid (Dronabinol): THX-110 for the treatment of Tourette syndrome (TS), for the treatment of Obstructive Sleep Apnea (OSA), and the treatment of Pain; THX-130 for the treatment of Mild Cognitive Impairment (MCI) and Traumatic Brain Injury (TBI); THX-150 for the treatment of infectious diseases; and THX-160 for the treatment of pain.

What is the price predicton of SPRC Stock?

Wall Street analysts forecast SPRC stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for SPRC is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Scisparc Ltd (SPRC)'s revenue for the last quarter?

Scisparc Ltd revenue for the last quarter amounts to 73.71 USD, decreased

What is Scisparc Ltd (SPRC)'s earnings per share (EPS) for the last quarter?

Scisparc Ltd. EPS for the last quarter amounts to USD, decreased

How many employees does Scisparc Ltd (SPRC). have?

Scisparc Ltd (SPRC) has 3 emplpoyees as of May 31 2026.

What is Scisparc Ltd (SPRC) market cap?

Today SPRC has the market capitalization of 5.62M USD.